Puma Biotechnology (PBYI) Return on Capital Employed (2012 - 2026)
Puma Biotechnology's (PBYI) quarterly Return on Capital Employed came in at 20.37% in Q1 2026, down 1117.0% YoY from 2.0% in Q1 2025, and down 29.92% on a QoQ basis from 29.07% in Q4 2025.
Puma Biotechnology (PBYI) Return on Capital Employed (2012 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 15 years of Return on Capital Employed data on file, last reported at 20.37% in Q1 2026.
- Quarterly Return on Capital Employed fell 1117.0% year-over-year to 20.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.37% (down 1117.0% YoY) and the FY2025 annual result came in at 27.93%, up 331.0% from the prior year.
- Return on Capital Employed slipped to 20.37% in Q1 2026, from 29.07% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 39.56% in Q2 2025 to a low of 14.05% in Q1 2022.
- A 5-year average of 20.76% and a median of 20.68% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 1764 bps — and 2023, when it soared 3196 bps.
- Tracing PBYI's Return on Capital Employed over 5 years: stood at 17.84% in 2022, then soared by 55 bps to 27.74% in 2023, then retreated by 8 bps to 25.61% in 2024, then grew by 13 bps to 29.07% in 2025, then fell by 30 bps to 20.37% in 2026.
- The last three Return on Capital Employed figures came in at 20.37% (Q1 2026), 29.07% (Q4 2025), and 28.89% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 21.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.30% |
| Mar 31, 2026 | 20.37% |
| Dec 31, 2025 | 29.07% |
| Sep 30, 2025 | 28.89% |
| Jun 30, 2025 | 39.56% |
| Mar 31, 2025 | 31.54% |
| Dec 31, 2024 | 25.61% |
| Sep 30, 2024 | 31.62% |
| Jun 30, 2024 | 17.96% |
| Mar 31, 2024 | 20.92% |
| Dec 31, 2023 | 27.74% |
| Sep 30, 2023 | 20.68% |
| Jun 30, 2023 | 15.69% |
| Mar 31, 2023 | 17.91% |
| Dec 31, 2022 | 17.84% |
| Sep 30, 2022 | 15.08% |
| Jun 30, 2022 | 6.55% |
| Mar 31, 2022 | -14.05% |
| Dec 31, 2021 | 1.19% |
| Sep 30, 2021 | -13.08% |